Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05559164 · ClinicalTrials.gov registry record · Phase 2
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
A Phase 2 study of Early Stage Breast Cancer and Cardiac Toxicity, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 10
- Study locations
NCT05559164 is a Phase 2 study of Early Stage Breast Cancer and Cardiac Toxicity that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 60 participants, below the 411-participant average among 21 other Early Stage Breast Cancer trials with a reported enrollment target (85% lower). The trial reports 10 study locations across 1 state.
The verdict
NCT05559164, a Phase 2 study of Early Stage Breast Cancer and Cardiac Toxicity, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.
Conditions Studied
Interventions
- DRUG Lipitor 40mg Tablet
Study Locations (10)
New Jersey
- Trinitas Hospital and Comprehensive Cancer Center - Elizabeth
- RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton - Hamilton
- RWJBarnabas Health - - Jersey City Medical Medical - Jersey City
- Monmouth Medical Center Southern Campus - Lakewood
- RWJBarnabas Health - Monmouth Medical Center - Long Branch
- Monmouth Community Medical - Long Branch
- Rutgers Cancer Institute of New Jersey - New Brunswick
- RWJBarnabas Health - Robert Wood Johnson University Hospital - New Brunswick
- RWJBarnabas Health - Newark Beth Israel Medical Center - Newark
- RWJBarnabas Health - Robert Wood Johnson University Hospital - Somerset
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-09-19 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05559164
The ClinicalTrials.gov registry entry for NCT05559164 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 411-participant average among 21 other Early Stage Breast Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Early Stage Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Lipitor 40mg Tablet is the first listed.
NCT05559164 reports 10 study locations spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05559164 about?
NCT05559164 is a clinical study titled "Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted". This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.
What is the current status of trial NCT05559164?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2022-09-19. Estimated completion is 2027-03-01.
What conditions does trial NCT05559164 study?
This clinical trial studies the following conditions: Early Stage Breast Cancer, Cardiac Toxicity.
What interventions are being tested in trial NCT05559164?
The interventions under investigation include: Lipitor 40mg Tablet (DRUG).
Who is sponsoring clinical trial NCT05559164?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05559164 being conducted?
This trial has 10 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Early Stage Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
RECRUITING · Phase 2
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
-
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
RECRUITING · Phase 2
-
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
RECRUITING · Phase 2
-
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
RECRUITING · Phase 2
-
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.